Foghorn therapeutics to participate at the william blair biotech focus conference 2021

Cambridge, mass., july 09, 2021 (globe newswire) -- foghorn therapeutics inc. (nasdaq: fhtx), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that adrian gottschalk, president & chief executive officer, is scheduled to participate in a panel at the william blair biotech focus conference 2021, which is being held virtually from july 14-15.
FHTX Ratings Summary
FHTX Quant Ranking